Lancet
PULSAR: Intravitreal Aflibercept 8 mg in nAMD
Lanzetta P, Korobelnik JF, Heier JS, et al
In the phase 3 PULSAR study, aflibercept 8 mg showed efficacy and safety with extended dosing intervals in patients with neovascular age-related macular degeneration, which has the potential to improve the management of these patients.
Previous Article
- • Deep Learning-Assisted Analysis of Biomarker Changes in Therapy-Resistant Neovascular Age-Related Macular Degeneration
- • Real-World Safety and Efficacy of 8 mg Aflibercept in nAMD
- • Case Report: Aflibercept for DME in Vitrectomized Eyes
- • Guideline Recommendations for Optimal Anti-VEGF Therapy in AMD
- • AI-Assisted Fluid Volume Analysis of Treatment-Naive nAMD in the Real World
- • Consecutive Monthly Loading Administrations of Aflibercept 8 Mg for Treatment-Naïve Exudative AMD
- • Outcomes of High-Dose Aflibercept in Exudative nAMD
- • PULSAR: Intravitreal Aflibercept 8 mg in nAMD
- • PHOTON: Intravitreal Aflibercept 8 mg in Diabetic Macular Edema
- • CANDELA: Aflibercept 8 mg in Patients With nAMD
